<qa>  What is the clinical hypothesis that subcutaneous Repatha QM will be well tolerated?The clinical hypothesis is that subcutaneous Repatha evolocumab QM will be well tolerated and will result in greater reduction of LDL-C, defined as percent change from baseline at week 24, compared with placebo QM in HIV-positive subjects with hyperlipidemia or mixed dyslipidemia. 